Tag: CLTI

No safety concerns and favourable patency at two years with Absorb...

The Absorb bioresorbable vascular scaffold (BVS; Abbott Vascular) can be used for the treatment of chronic limb-threatening ischaemia (CLTI) patients in infrapopliteal arteries with...
CLTI

CDC recognises and codifies critical limb-threatening ischaemia in ICD-10-CM

A coalition organised by the CLI Global Society has announced its proposal to distinctly recognise "critical limb ischaemia" (CLI) and "chronic limb-threatening ischaemia" (CLTI)...
deep vein arterialisation

Deep vein arterialisation should be considered in “no option” CLTI patients,...

Midterm results from a study of the largest population of patients with no-option chronic limb-threatening ischaemia (CLTI) treated with percutaneous deep vein arterialisation (pDVA)...

Systematic review and meta-analysis finds “substantial” one-year mortality rate in octogenarians...

In octogenarians with chronic limb-threatening ischaemia (CLTI), researchers found a one-year mortality rate of 32% after revascularisation, which was significantly higher than in non-octogenarians....

MERLION trial six-month outcomes presented at VIVA late-breaking trial session

Six-month clinical outcomes of the MERLION trial were presented as part of the VIVA Late-Breaking Clinical Trials Livesteam (25 June), by Tjun Tang (Singapore...
Rexgenero

Rexgenero acquires the key technology and programme assets of aratinga.bio SAS...

Rexgenero, a regenerative medicine company developing advanced cell therapies to treat chronic limb-threatening ischaemia (CLTI), has announced the acquisition of all the key assets...
pedal

Pedal artery revascularisation: Is it ready for prime time?

Reviewing the available evidence for below-the-ankle interventions in the treatment of critical limb-threatening ischaemia (CLTI), Srini Tummala proposes that pedal artery intervention “should be...
revascularisation

Veterans study suggests surgery is still dominant revascularisation approach for critical...

A review of data from Veteran Health Administration shows that there was a temporal increase in the use of revascularisations for the management of...

New meta-analysis finds “no observed difference” in mortality between paclitaxel and...

February 2020 brings another paclitaxel device meta-analysis of randomised controlled trials in chronic limb-threatening ischaemia (CLTI) patients. Krystal Dinh (Westmead Hospital, Sydney, Australia) et...
Vascular Experts give their thoughts on meta-analysis

Vascular surgeons and cardiologists respond to new meta-analysis of PCBs in...

Vascular and interventional cardiology experts including Kim Hodgson (Springfield, USA), Ramon Varcoe (Sydney, Australia) and Gary Ansel (Columbus, USA) give their thoughts on the...
interventional radiology experts

IR experts respond to new meta-analysis of paclitaxel-coated balloons in infrapopliteal...

A range of interventional radiologists experts including Michael Dake (Tucson, USA), John Kaufman (Portland, USA), Jim Reekers (Amsterdam, The Netherlands) and Gunnar Tepe (Rosenheim,...

LimFlow receives FDA approval for US study of minimally-invasive technology designed...

LimFlow has announced that the US Food and Drug Administration (FDA) has approved its investigational device exemption (IDE) for the PROMISE II pivotal study of...